Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to -$20.5 million.

  • GeneDx Holdings' Change in Accured Expenses fell 165.73% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year increase of 49.69%. This contributed to the annual value of -$20.5 million for FY2024, which is 56.42% up from last year.
  • As of FY2024, GeneDx Holdings' Change in Accured Expenses stood at -$20.5 million, which was up 56.42% from -$47.0 million recorded in FY2023.
  • GeneDx Holdings' 5-year Change in Accured Expenses high stood at $34.5 million for FY2022, and its period low was -$47.0 million during FY2023.
  • In the last 3 years, GeneDx Holdings' Change in Accured Expenses had a median value of -$20.5 million in 2024 and averaged -$11.0 million.
  • As far as peak fluctuations go, GeneDx Holdings' Change in Accured Expenses soared by 62.38% in 2021, and later slumped by 236.26% in 2023.
  • GeneDx Holdings' Change in Accured Expenses (Yearly) stood at $16.0 million in 2020, then soared by 62.38% to $25.9 million in 2021, then surged by 32.96% to $34.5 million in 2022, then plummeted by 236.26% to -$47.0 million in 2023, then spiked by 56.42% to -$20.5 million in 2024.